文献速递慢阻肺

辛伐他汀能否减少慢阻肺急性加重?一项随机双盲对照研究

Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.
PubMed 文献 · Eur Respir J · 2021-07-29

这项单中心随机双盲安慰剂对照试验纳入209例GOLD 2-4级慢阻肺患者,比较辛伐他汀40 mg/日与安慰剂治疗12个月的效果。辛伐他汀组首次急性加重时间显著延长(中位341天 vs 140天,p<0.001),急性加重率显著降低(41% vs 59%,p=0.003),但对生活质量、肺功能、6分钟步行试验和高敏C反应蛋白无影响。

要点

  • 辛伐他汀40 mg/日延长慢阻肺首次急性加重时间,中位341天 vs 140天。
  • 辛伐他汀组急性加重率显著降低(41% vs 59%,p=0.003)。
  • 对生活质量、肺功能、6分钟步行试验和hs-CRP无显著影响。

核心结论

  • 在这项单中心随机对照试验中,辛伐他汀40 mg/日显著延长了慢阻肺首次急性加重时间并降低了急性加重率。

研究设计与样本

  • 随机双盲安慰剂对照单中心试验,纳入符合GOLD 2-4级标准的慢阻肺患者209例。
  • 辛伐他汀组105例接受40 mg/日,安慰剂组104例,计划治疗12个月,主要终点为首次急性加重时间。

主要发现

  • 辛伐他汀组首次急性加重时间中位341天,安慰剂组140天(log-rank检验p<0.001)。
  • 辛伐他汀组首次急性加重风险HR为0.51(95%CI 0.34-0.75;p=0.001)。
  • 急性加重发生率辛伐他汀组103次(41%),安慰剂组147次(59%)(p=0.003)。
  • 年化急性加重率辛伐他汀组1.45次/患者年,安慰剂组1.9次/患者年(发生率比0.77,95%CI 0.60-0.99)。
  • 生活质量、肺功能、6分钟步行试验和高敏C反应蛋白未见显著影响。

临床怎么用

  • 对于GOLD 2-4级慢阻肺患者,辛伐他汀40 mg/日可能作为减少急性加重的辅助治疗选择。
  • 使用辛伐他汀时需注意脱落率较高(辛伐他汀组39例 vs 安慰剂组29例)。

局限性

  • 单中心研究,结果外推需谨慎。
  • 辛伐他汀组脱落人数多于安慰剂组(39 vs 29)。
  • 未报告生活质量、肺功能等次要终点具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have shown that statins have beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation. METHODS: We performed a randomised double-blind placebo-controlled single-centre trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for Chronic Obstructive Lung Disease criteria grades 2-4 at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12 months and the main outcome parameter was time to first exacerbation. RESULTS: Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo: median 341 versus 140 days (log-rank test p<0.001). Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34-0.75; p=0.001). Rate of exacerbations was significantly lower with simvastatin: 103 (41%) versus 147 (59%) (p=0.003). The annualised exacerbation rate was 1.45 events per patient-year in the simvastatin group and 1.9 events per patient-year in the placebo group (incidence rate ratio 0.77, 95% CI 0.60-0.99). We found no effect on quality of life, lung function, 6-min walk test and high-sensitivity C-reactive protein. More patients dropped out in the simvastatin group compared to the placebo group (39 versus 29). CONCLUSION: In our single-centre RCT, simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Schenk P, Spiel AO, Hüttinger F, et al. Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study. Eur Respir J. 2021. PMID: 33574076. doi:10.1183/13993003.01798-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。